Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

Statins Might Help in HFpEF—Even in the Absence of ASCVD

Todd Neale

May 01, 2024

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

Advertisement

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

AHA Statement Outlines Cardiac Contributions to Brain Health

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Statins Might Help in HFpEF—Even in the Absence of ASCVD

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Guideline-Directed Therapies Underused in Frail HF Patients

FDA Approves Empagliflozin for Treatment of HFpEF

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

FDA Approves Dapagliflozin for CKD Patients

FDA Approves Vericiguat for High-risk Patients With HF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content